v3.20.4
Licensing, Acquisitions, and Other Arrangements - Acquisition of Allergan (Details) - USD ($)
$ / shares in Units, $ in Millions
8 Months Ended 12 Months Ended
May 08, 2020
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Business Acquisition          
Closing price of AbbVie common stock (in dollars per share) $ 83.96        
Amortization of intangible assets     $ 5,805 $ 1,553 $ 1,294
Fair Value of Assets Acquired and Liabilities Assumed          
Goodwill   $ 33,124 33,124 15,604 $ 15,663
Allergan plc          
Business Acquisition          
Cash per share received by Allergan shareholders (in dollars per share) $ 120.30        
Amount of AbbVie stock per share received by Allergan shareholders (in shares) 0.8660        
Allergan ordinary shares outstanding at closing (in shares) 330,000,000        
Shares of AbbVie's common stock issued to Allergan shareholders (in shares) 286,000,000        
Stock options issued to Allergan's equity award holders (in shares) 11,200,000        
Business Combination, Number of RSUs Issued to Equity Award Holders of Acquiree 8,200,000        
Property and equipment measurement period adjustments     215    
Other net measurement period adjustments to identifiable net assets     73    
Goodwill measurement period adjustments     (10,000)    
Fair value step-up adjustment to inventories $ 1,200        
Fair value step-up adjustment to inventories amortization period   1 year      
Weighted average useful life of acquired intangible assets   12 years      
Fair value of purchase price adjustment to long-term debt 1,300        
Net revenues attributable to Allergan from acquisition date   $ 10,300      
Operating losses attributable to Allergan from acquisition date   1,100      
Amortization of intangible assets   4,000      
Inventory fair value step-up amortization   $ 1,200      
Consideration Transferred          
Cash consideration paid to Allergan shareholders [1] 39,675        
Fair value of AbbVie common stock issued to Allergan shareholders [2] 23,979        
Fair value of AbbVie equity stock issued to Allergan equity award holders [3] 430        
Total consideration 64,084        
Fair Value of Assets Acquired and Liabilities Assumed          
Cash and equivalents 1,537        
Short-term investments 1,421        
Accounts receivable 2,374        
Inventories 2,340        
Prepaid expenses and other current assets 1,982        
Investments 137        
Property and equipment 2,127        
Intangible assets - Developed product rights 67,330        
Intangible assets - In-process research and development 1,750        
Other noncurrent assets 1,395        
Short-term borrowings (60)        
Current portion of long-term debt and finance lease obligations (1,899)        
Accounts payable and accrued liabilities (5,852)        
Long-term debt and finance lease obligations (18,937)        
Deferred income taxes (3,792)        
Other long-term liabilities (4,765)        
Total identifiable net assets 47,088        
Goodwill 16,996        
Total assets acquired and liabilities assumed $ 64,084        
Pro Forma Information          
Net revenues     50,521 49,028  
Net earnings (loss)     6,746 (38)  
Allergan plc | Developed product rights intangible assets          
Business Acquisition          
Intangible assets measurement period adjustments     9,100    
Allergan plc | IPR&D intangible assets          
Business Acquisition          
Intangible assets measurement period adjustments     710    
Allergan plc | Selling, general and administrative          
Business Acquisition          
Acquisition-related expenses     $ 781 $ 103  
[1] Represents cash consideration transferred of $120.30 per outstanding Allergan ordinary share based on 330 million Allergan ordinary shares outstanding at closing.
[2] Represents the acquisition date fair value of 286 million shares of AbbVie common stock issued to Allergan shareholders based on the exchange ratio of 0.8660 AbbVie shares for each outstanding Allergan ordinary share at the May 8, 2020 closing price of $83.96 per share.
[3] Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.